2018 Charitable Giving Dips, as Predicted
A Giving USA report released last week shows that US households’ charitable donations in 2018 experienced the largest decline since the Great Recession. We hate to say we told you so, but we told you so.
Action on Climate Change Should Not Include Creation of New Entitlements
Over the last two years, the United States has scaled back Obama-era climate change policies, withdrawing from the Paris Agreement and rolling back climate-related regulations.
Carbon Tax Most Efficient in Tackling Climate Change
It is encouraging to see more and more fellow Republicans shed the reflexive skepticism about climate change that has characterized the GOP for years. Now, Republicans need to offer solutions.
Costs of the Green New Deal
With the government reopened (at least for now), Speaker Nancy Pelosi is poised to begin advancing her party’s policy agenda. High on the list will be the loosely-defined Green New Deal, a federal spending program that will cost $2 trillion, $5.7 trillion, or more, and move the electric power sector to complete reliance on renewable energy sources.
The US labor market data is great. What does it mean for this year’s midterms?
Tomorrow, the American public will get a fresh glimpse at the state of the US labor market. The Bureau of Labor Statistics’ (BLS) release of the September employment report, which will be the next-to-last before the upcoming election, will provide voters new insight on job growth and unemployment rates.
Happy Birthday, FDA Tobacco Plan!
Just over a year ago, the Food and Drug Administration (FDA) announced a bold new plan to reduce nicotine in cigarettes to non-addictive levels and encourage the development of non-combustible nicotine products. Key to the FDA’s approach is an acknowledgement of both the continuum of risks associated with various nicotine delivery mechanisms and the opportunity for innovative products to reduce the health risks associated with tobacco consumption
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
- A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax Reform
- New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
- Congress on the Brink of Disrupting the PBM Market
- Raising the Salt Cap Would Increase Tax Complexity
